CureVac N.V. (CVAC) has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The study is expected to include more than 35,000 participants at sites in Europe and Latin America.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

CureVac N.V. (CVAC) has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The study is expected to include more than 35,000 participants at sites in Europe and Latin America.

RTTNews | Dec 14, 2020 01:13AM EST

01:13 Monday, December 14, 2020 (RTTNews.com) - CureVac N.V. (CVAC) has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The study is expected to include more than 35,000 participants at sites in Europe and Latin America.

The company said this HERALD trial will start with an initial Phase 2b part, which is expected to seamlessly merge into a Phase 3 efficacy trial. Subjects 18 years of age or older will be enrolled at multiple sites and will receive a two-dose schedule of either SARS-CoV-2 or placebo.

Read the original article on RTTNews ( https://www.rttnews.com/3153232/curevac-begins-phase-2b-3-study-for-development-of-covid-19-vaccine-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved